论文信息 - Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer - 字舞流文

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

H. Ueno | J. Furuse | K. Mizumoto | Y. Hamamoto | A. Cheng | S. Egawa | T. Okusaka | K. Yamao | H. Miyakawa | T. Hatori | H. Maguchi | S. Nakamori | H. Fujii | T. Ioka | N. Boku | S. Ohkawa | A. Funakoshi | A. Sato | Y. Ohashi | T. Yamaguchi | S. Matsumoto | J. S. Chen | T. Ito | T. Satoh | M. Tanaka

[1] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[2] H. Ueno,et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[4] S. Dubnicka. A confidence interval for the median of a finite population under unequal probability sampling: A model-assisted approach , 2007 .

[5] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[7] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8] Ron Brookmeyer,et al. A Confidence Interval for the Median Survival Time , 1982 .